Literature DB >> 7257058

Photochemotherapy and the eye: photoprotective factors.

W B Glew, G McKeever, W P Roberts, G Malinin, T P Nigra.   

Abstract

The photosensitizer, 8-Methoxypsoralen, binds reversibly to a greater extent to human serum albumin than to human lens in the absence of UVA irradiation. Since experimental and clinical evidence suggests that peak levels in skin exceed those in plasma, which in turn exceed those in the lens, 5 to 10 fold more UVA is required to induce lenticular injury than to produce a threshold skin effect. To prevent the potential photoactivation of residual of 8-MOP in the lens, UVA opaque wraparound sunglasses should be worn for 24 hours after drug ingestion. Glasses with limited UVA transmission but good visible transmission should be worn after the 24 hour period following drug ingestion or indoors during the first 24 hours as a substitute for the wraparound. Every effort should be made to insure complete compliance in the wearing of UVA photoprotective lenses by all psoralen photosensitized patients.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7257058      PMCID: PMC1312142     

Source DB:  PubMed          Journal:  Trans Am Ophthalmol Soc        ISSN: 0065-9533


  13 in total

Review 1.  Binding of drugs by albumin and plasma protein.

Authors:  J J Vallner
Journal:  J Pharm Sci       Date:  1977-04       Impact factor: 3.534

2.  Dermatological and ocular examinations in rabbits chronically photosensitized with methoxsalen.

Authors:  J A Parrish; L T Chylack; M E Woehler; H M Cheng; M A Pathak; W L Morison; J Krugler; W F Nelson
Journal:  J Invest Dermatol       Date:  1979-09       Impact factor: 8.551

3.  Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light.

Authors:  J A Parrish; T B Fitzpatrick; L Tanenbaum; M A Pathak
Journal:  N Engl J Med       Date:  1974-12-05       Impact factor: 91.245

4.  Psoralen plus black light inhibits epidermal DNA synthesis.

Authors:  J F Walter; W H Kelsey; J J Voorhees; E A Duell
Journal:  Arch Dermatol       Date:  1973-06

5.  Photosensitization of the eye by 8-methoxypsoralen.

Authors:  R G Freeman; D Troll
Journal:  J Invest Dermatol       Date:  1969-12       Impact factor: 8.551

6.  Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial.

Authors:  J W Melski; L Tanenbaum; J A Parrish; T B Fitzpatrick; H L Bleich
Journal:  J Invest Dermatol       Date:  1977-06       Impact factor: 8.551

7.  Reversible binding of 5- and 8-methoxypsoralen to human serum proteins (albumin) and to epidermis in vitro.

Authors:  M Artuc; G Stuettgen; W Schalla; H Schaefer; J Gazith
Journal:  Br J Dermatol       Date:  1979-12       Impact factor: 9.302

8.  The binding of 8-methoxypsoralen by human serum albumin.

Authors:  F M Veronese; R Bevilacqua; O Schiavon; G Rodighiero
Journal:  Farmaco Sci       Date:  1978-09

9.  Risk of cutaneous carcinoma in patients treated with oral methoxsalen photochemotherapy for psoriasis.

Authors:  R S Stern; L A Thibodeau; R A Kleinerman; J A Parrish; T B Fitzpatrick
Journal:  N Engl J Med       Date:  1979-04-12       Impact factor: 91.245

10.  Plasma levels of 8-methoxypsoralen determined by high-pressure liquid chromatography in psoriatic patients ingesting drug from two manufacturers.

Authors:  B Ljunggren; D M Carter; J Albert; T Reid
Journal:  J Invest Dermatol       Date:  1980-01       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.